The educational platform is targeted at HCPs and their staff.
Stock.adobe.com
AbbVie launched a new learning platform designed to provide hcps, staff, and management about the company’s Allergan Aesthetics brand and products.1 The platform is available for free for all Allergan Aesthetics customers and is part of AbbVie’s investment in its AMI platform.
In a press release, U.S. Allergan Aesthetics senior vice president Glen Curran said, “Allergan Aesthetics designed AMI Business to meet providers where they are—supporting them with practical, business-focused education related to our products to complement their clinical expertise and help them grow their practices and deliver on patient needs. We are excited to provide these courses free of charge through AMI Online, giving all of our customers access to valuable resources that help them thrive in this dynamic industry."
Allergan Aesthetics develops, manufactures, and markets a portfolio of aesthetics brands and products, including facial injectables, body contouring, plastics, and skin care. The new learning platform will include educational material about the brand’s products, along with broader business-centered modules. This includes lessons on goals setting and creating lifetime patient partnerships.
In the same press release, board-certified plastic surgeon Dr. Joseph A. Russo said, “As a clinician and an educator in the aesthetic space, one of the biggest challenges we face is running and growing a business while improving our clinical skills to provide great outcomes for our patients. The AMI Business modules offer valuable insights for growing practices."
AbbVie also recently announced the winners of its first Migraine Career Catalyst Award, which is focused on telling the stories of migraine-sufferers navigating their careers while also managing their condition.2
In a press release issued at the time, AbbVie senior vice president and president of neuroscience and eye care Jag Dosanjh said, “Migraine can significantly affect an individual's career trajectory and long-term potential. Despite these challenges, the recipients of the inaugural AbbVie Migraine Career Catalyst Award have shared their remarkable determination to overcome disease-related obstacles as they work toward their professional aspirations. As the only company with three treatment options that collectively address the entire spectrum of migraine, we have a deep understanding of the challenges that people living with migraine can face in the workplace, and we're proud to support these individuals as they lead lives that transcend obstacles often imposed by the impact of the disease."
Melissa, a migraine-sufferer from Davis, West Virginia, is one of the winners of this year’s contest. In the same press release, she discussed her experience, saying, “Migraine impacted my life in ways that I hadn't anticipated. I spent most of my career working in state parks, outdoor recreation, and tourism. However, the demands of public service combined with the unpredictability of migraine have made life incredibly challenging. This award will allow me to create a mentorship program in my small town and share my experience and knowledge in outdoor recreation with the next generation, ensuring that they are better equipped to navigate the challenges of their careers with or without migraine."
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 18th 2025Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in multiple myeloma and solid tumor bone metastases.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.